enGene Therapeutics ENGN
NASDAQ ENGN
$1.58 -0.05 (-3.07%)
At close: Oct 22, 2026 · 4:00 PM EDT

enGene Therapeutics (ENGN) Other financing activities (2024 - 2026)

Updated

enGene Therapeutics (ENGN) reported Other financing activities of -$70,000 for fiscal Q2 2026 (quarter ended Apr 30, 2026).

Analysis

enGene Therapeutics (ENGN) Other financing activities (2024 - 2026) Analysis & Trends

For FY2024 (ended Oct 31, 2024), enGene Therapeutics posted Other financing activities of $585,000.

  • By fiscal year, Other financing activities came in at $391,000 in FY2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,230.11 Bn 1,198.70 Bn 19.71 Bn
2 Johnson & Johnson 644.39 Bn 564.25 Bn 17.30 Bn
3 AbbVie 503.52 Bn 476.68 Bn 12.70 Bn
4 Merck 363.29 Bn 317.72 Bn 12.21 Bn
5 Novartis Ag 298.23 Bn 262.62 Bn 11.24 Bn
6 Astrazeneca 267.53 Bn 241.29 Bn 12.86 Bn
7 Amgen 241.80 Bn 197.20 Bn 7.24 Bn
8 Gilead Sciences 195.07 Bn 169.19 Bn 6.22 Bn
9 Pfizer 173.33 Bn 120.28 Bn 10.94 Bn
10 enGene Therapeutics 105.88 Mn -888.59 Mn -
Historic Data

Historic Data

Download Data
DateValue
Apr 30, 2026 70,000.00
Jan 31, 2026 -10.06 Mn
Apr 30, 2024 -143,000.00
Jan 31, 2024 -442,000.00
API Access

enGene Therapeutics Other financing activities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=other-financing-activities&ticker=ENGN&period=max&api_key=YOUR_API_KEY